• Mutation; HGNC; HGNC:3236; EGFR; Simple; p.Leu747_Glu749del (c.2239_2247delTAAGAGAA); ClinVar=VCV000177765; Zygosity=Heterozygous (from parent cell line).
  
• Mutation; HGNC; HGNC:11998; TP53; Simple; p.Tyr205His (c.613T>C); ClinVar=VCV000376685; Zygosity=Homozygous (from parent cell line).
  

PubMed=32928921; DOI=10.1158/0008-5472.CAN-20-1634; PMCID=PMC11106563
Yu-Ting Sun, Brooke A. Meyers, Barbara Czako, Paul Leonard, Faika Mseeh, Angela L. Harris, Qi Wu, Sarah Johnson, Connor A. Parker, Jason B. Cross, Maria Emilia Di Francesco ...Show all 45 authors... , Benjamin J. Bivona, Christopher A. Bristow, Jason P. Burke, Caroline C. Carrillo, Christopher L. Carroll, Qing Chang, Ning-Ping Feng, Guang Gao, Sonal Gera, Virginia Giuliani, Justin K. Huang, Yong-Ying Jiang, Zhi-Jun Kang, Jeffrey J. Kovacs, Chiu-Yi Liu, Anastasia M. Lopez, Xiao-Yan Ma, Pijus K. Mandal, Timothy J. McAfoos, Meredith A. Miller, Robert A. Mullinax, Michael Peoples, Vandhana Ramamoorthy, Sahil Seth, Nakia D. Spencer, Erika Suzuki, Christopher C. Williams, Simon S. Yu, Andy M. Zuniga, Giulio F. Draetta, Joseph R. Marszalek, Timothy P. Heffernan, Nancy E. Kohl, Philip Jones; Show fewer authors
Allosteric SHP2 inhibitor, IACS-13909, overcomes EGFR-dependent and EGFR-independent resistance mechanisms toward osimertinib.
Cancer Res. 80:4840-4853(2020)